GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (STU:0ET) » Definitions » EV-to-FCF

Esperion Therapeutics (STU:0ET) EV-to-FCF : -16.88 (As of Jun. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Esperion Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Esperion Therapeutics's Enterprise Value is €430.1 Mil. Esperion Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-25.5 Mil. Therefore, Esperion Therapeutics's EV-to-FCF for today is -16.88.

The historical rank and industry rank for Esperion Therapeutics's EV-to-FCF or its related term are showing as below:

STU:0ET' s EV-to-FCF Range Over the Past 10 Years
Min: -90.64   Med: -3.42   Max: -0.5
Current: -16.5

During the past 13 years, the highest EV-to-FCF of Esperion Therapeutics was -0.50. The lowest was -90.64. And the median was -3.42.

STU:0ET's EV-to-FCF is ranked worse than
100% of 532 companies
in the Drug Manufacturers industry
Industry Median: 22.76 vs STU:0ET: -16.50

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-04), Esperion Therapeutics's stock price is €1.921. Esperion Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.917. Therefore, Esperion Therapeutics's PE Ratio for today is At Loss.


Esperion Therapeutics EV-to-FCF Historical Data

The historical data trend for Esperion Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics EV-to-FCF Chart

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.20 -5.62 -1.16 -3.20 -3.97

Esperion Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.25 -1.61 -1.84 -3.97 -19.94

Competitive Comparison of Esperion Therapeutics's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's EV-to-FCF falls into.



Esperion Therapeutics EV-to-FCF Calculation

Esperion Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=430.108/-25.477
=-16.88

Esperion Therapeutics's current Enterprise Value is €430.1 Mil.
Esperion Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-25.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Esperion Therapeutics  (STU:0ET) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Esperion Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.921/-0.917
=At Loss

Esperion Therapeutics's share price for today is €1.921.
Esperion Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.917.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Esperion Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics (STU:0ET) Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.

Esperion Therapeutics (STU:0ET) Headlines

No Headlines